- Franken MD, van Rooijen EM, May AM, Koffijberg H, van Tinteren H, Mol L, ten Tije AJ, Creemers GJ, van der Velden AMT, Tanis BC, Uyl-de Groot CA, Punt CJA, Koopman M, van Oijen MGH, Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. EUR J CANCER 2017;75:204-212 [PubMed]
- ter Veer E, van Oijen MGH, van Laarhoven HWM, S-1 with leucovorin and oxaliplatin for advanced gastric cancer. LANCET ONCOL 2016;17 (2):E41 [PubMed]
- ter Veer E, Haj Mohammad N , van Valkenhoef G, Ngai LL, Mali RMA, Anderegg MC, van Oijen MGH, van Laarhoven HWM, The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. JNCI-J NATL CANCER I 2016;108 (10):djw166 [PubMed]
- Belderbos TDG, van Oijen MGH, Moons LMG, Siersema PD, The "golden retriever" study: improving polyp retrieval rates by providing education and competitive feedback. GASTROINTEST ENDOSC 2016;83 (3):596-601 [PubMed]
- Bromley EG, May FP, Federer L, Spiegel BMR, van Oijen MGH, Explaining persistent under-use of colonoscopic cancer screening in African Americans: A systematic review. PREV MED 2015;71:40-48 [PubMed]
Martijn van Oijen PhD is Evaluation of Cancer Care programleader of the Cancer Center Amsterdam. He is a principal investigator appointed as Associate Professor at the department of Medical Oncology at the Academic Medical Center (AMC), Amsterdam. Concurrently, he serves as methodology consultant for IKNL, and is a member of the scientific committee of PALGA.
He studied biomedical sciences with two majors -epidemiology and health technology assessment- and obtained his PhD at the Radboud University Medical Center. Dr. van Oijen has worked as an Assistant Professor at UMC Utrecht and as Associate Professor and Associate Director of the Quality Initiative at the University of California Los Angeles (UCLA).
Evaluation of Cancer Care
Dr. van Oijen's research group focuses on improving the quality of cancer care by forming and analyzing large datasets, combined with state of the art information technology, including decision support tools and wearable technology. His research can be described in three research topics:
Quality of care
Data from large existing available datasets, such as the Dutch Cancer Registry or the nationwide pathology database PALGA, are studied for treatment patterns, guideline adherence and health outcomes using state of the art statistical methodology. His group is highly involved in linking these datasets and the process of enrichment with patient-reported outcomes and biomaterial for gastrointestinal cancer in the 3P-projects (PACAP, POCOP and PLCRC)
This research focuses on translation from results of clinical trials and cohort studies towards implementation in clinical practice. Using Bayesian network meta-analyses, and cost-effectiveness research, input for digital decision support tools is generated. These tools, e.g. IBM Watson for Oncology, are then evaluated in clinical practice in a framework for optimal cancer care.
Cancer care is mostly focused on in-hospital contacts and services, but most events occur out-of-hospital. Using wearable technology, objective, passively collected, information becomes available about the patient journey. When properly interpreted with user-friendly dashboards, this can result in value-based cancer care.
Dr. M.G.H. van Oijen PhD
W.P.M. Dijksterhuis MD
Drs. E. ter Veer
Drs. T.D. Belderbos MD (UMC Utrecht)
Drs. M.D. Franken (UMC Utrecht)
Drs. K. Goey (UMC Utrecht)
M.K. Bos BA
Prof. dr. C.J.A. Punt MD PhD (Clinical and translational research in gastrointestinal cancer, with focus on colorectal cancer)
- Membership of editorial board / Editorship, ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Membership of medical or scientific committee, PALGA
- Methodological Consultant, IKNL
- Integraal Kankercentrum Nederland
- Merck BV
- Nordic Pharma B.V.
- Roche Nederland B.V.
- Servier Nederland Farma B.V.